pyrazines has been researched along with canertinib dihydrochloride in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (77.27) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Courtney, CL; Dominick, MA; Kim, SN; Walsh, KM; Watkins, JR | 1 |
| Chevalier, P; Kuznetsov, V; Robinson, RB; Rosen, MR | 1 |
| Brodfuehrer, JI; Bullen, WW; Walter, GA; Whitfield, LR | 1 |
| Braguer, D; Briand, C; Carles, G; Garcia, P | 2 |
| Barasoain, I; Briand, C; de Ines, C; Garcia, P; Leynadier, D; Peyrot, V; Rener, GA; Temple, C | 1 |
| MacDonald, JR; Pegg, DG | 1 |
| Delpón, E; Pérez, O; Tamargo, J; Valenzuela, C | 1 |
| Hook, KE; Leopold, WR; Przybranowski, SA | 1 |
| Cheson, BD; Ho, PT; Phillips, PH; Wright, J | 1 |
| Markoglou, N; Wainer, IW | 1 |
| Benson, L; Einzig, AI; Grove, WR; Lathia, CD; Roca, J; Sklarin, NT; Thomas, S; Wiernik, PH | 1 |
| Abbruzzese, JL; Ajani, J; Diaz-Canton, E; Grove, W; Meyers, C; Patt, Y; Pazdur, R | 1 |
| Conrad, CA; Edwards, CL; Forman, A; Freedman, RS; Grothey, A; Grove, W; Hasenburg, A; Kavanagh, JJ; Kudelka, AP; Meyers, CA; Varma, D; Verschraegen, CF | 1 |
| Benjamin, RS; Burgess, MA; Gray, R; Jenkins, J; Papadopolous, NE; Patel, SR; Plager, C; Sidhu, G | 1 |
| Bowling, MK; Donehower, RC; Grochow, LB; Long, GS; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Conrad, CA; Gelke, CK; Grove, W; Kudelka, AP; Meyers, CA; Pazdur, R | 1 |
| Vandré, DD; Weitzel, DH | 1 |
| Ansari, RH; Kugler, JW; Richards, JM; Ryan, CW; Shulman, KL; Sosman, JA; Vogelzang, NJ; Vokes, EE | 1 |
| Didolkar, MS; Eckardt, JR; Flaherty, LE; Samlowski, W; Sondak, VK; Taylor, SA; Unger, JM; Whitehead, RP | 1 |
| Balcerzak, SP; Galloway, S; Kraut, EH; Moore, T; Thomas, JP; Vandre, DD | 1 |
| Fine, H; Hess, K; Jaeckle, K; Kunschner, LJ; Kyritsis, AP; Yung, WK | 1 |
11 trial(s) available for pyrazines and canertinib dihydrochloride
| Article | Year |
|---|---|
Determination of the anticancer agent CI-980 in plasma by achiral liquid chromatography on a Pirkle-type stationary phase.
Topics: Antineoplastic Agents; Carbamates; Child; Chromatography, Liquid; Humans; Neoplasms; Pyrazines; Pyridines; Sensitivity and Specificity; Stereoisomerism | 1997 |
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbamates; Central Nervous System Diseases; Drug Tolerance; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Pyridines | 1997 |
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyrazines; Pyridines | 1997 |
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Carbamates; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Humans; Hyponatremia; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Phlebitis; Pyrazines; Pyridines; Survival Rate; Treatment Outcome | 1998 |
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carbamates; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pyrazines; Pyridines; Sarcoma; Treatment Outcome | 1998 |
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia | 1997 |
Neurotoxicity of CI-980, a novel mitotic inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Cognition; Cognition Disorders; Colorectal Neoplasms; Female; Humans; Male; Memory; Memory Disorders; Middle Aged; Neuropsychological Tests; Neurotoxins; Ovarian Neoplasms; Pyrazines; Pyridines | 1997 |
CI-980 in advanced melanoma and hormone refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carbamates; Drug Resistance, Neoplasm; Female; Humans; Male; Melanoma; Middle Aged; Prostatic Neoplasms; Pyrazines; Pyridines | 2000 |
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Pyrazines; Pyridines; Skin Neoplasms; Survival Rate; Treatment Outcome | 2001 |
A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Carcinoma, Small Cell; Female; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pyrazines; Pyridines | 2002 |
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glioma; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Survival Rate; Thrombocytopenia; Treatment Outcome | 2002 |
11 other study(ies) available for pyrazines and canertinib dihydrochloride
| Article | Year |
|---|---|
Proliferative bone lesions in rats given anticancer compounds.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Development; Bone Diseases; Bone Marrow; Carbamates; Cell Division; Drug Combinations; Female; Glucuronates; Injections, Intravenous; Male; Pentostatin; Pyrazines; Pyridines; Rats; Rats, Inbred Strains; Trimetrexate | 1991 |
Tubulin binding agent CI-980 has positive inotropic and local anesthetic actions.
Topics: Action Potentials; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Calcium; Carbamates; Cardiotonic Agents; Cells, Cultured; Dogs; Electrophysiology; Heart; In Vitro Techniques; Microelectrodes; Models, Biological; Myocardial Contraction; Myocardium; Purkinje Fibers; Pyrazines; Pyridines; Rats; Tubulin | 1994 |
High-performance liquid chromatographic assay for CI-980, a novel 1-deaza-7,8-dihydropteridine anticancer agent, in human plasma and urine.
Topics: Antineoplastic Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Freezing; Humans; Pyrazines; Pyridines; Reproducibility of Results; Spectrometry, Fluorescence | 1995 |
Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cell Division; Colchicine; Demecolcine; Docetaxel; Humans; KB Cells; Microscopy, Fluorescence; Microscopy, Immunoelectron; Microtubule Proteins; Microtubules; Paclitaxel; Pyrazines; Pyridines; Taxoids; Tubulin | 1995 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.
Topics: Animals; Antineoplastic Agents; Carbamates; Cell Cycle; Cell Line; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Mice; Microtubule Proteins; Microtubules; Pyrazines; Pyridines; Tumor Cells, Cultured | 1994 |
Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Carbamates; Depression, Chemical; Extravasation of Diagnostic and Therapeutic Materials; Injections, Intradermal; Irritants; Male; Mice; Mice, Inbred BALB C; Mitosis; Pyrazines; Pyridines; Skin Ulcer; Vinblastine | 1993 |
Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Carbamates; Female; Guinea Pigs; In Vitro Techniques; Male; Papillary Muscles; Pyrazines; Pyridines; Sodium Channel Blockers | 1997 |
Cellular transport of CI-980.
Topics: Animals; Antineoplastic Agents; Biological Transport; Carbamates; Carrier Proteins; Cattle; CHO Cells; Cricetinae; Dipyridamole; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Leukemia L1210; Platelet Aggregation Inhibitors; Pyrazines; Pyridines; Stereoisomerism | 1996 |
Clinical Trials. Referral resource Clinical trials using CI-980 (mivobulin isethionate).
Topics: Antineoplastic Agents; Carbamates; Clinical Trials as Topic; Humans; Pyrazines; Pyridines | 1997 |
Differential spindle assembly checkpoint response in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Carbamates; Fluorescent Antibody Technique, Indirect; Giant Cells; Humans; Lung Neoplasms; Microtubules; Mitosis; Pyrazines; Pyridines; Spindle Apparatus; Tumor Cells, Cultured | 2000 |